目的:评价活化自体淋巴细胞过继性免疫治疗(adoptive immunotherapy,AIT)是否有助于改善原发性肝细胞癌的临床疗效。方法:选取2016年8月至2018年12月在中国人民解放军总医院第五医学中心确诊的64例原发性肝细胞癌患者,通过分层随机法分...目的:评价活化自体淋巴细胞过继性免疫治疗(adoptive immunotherapy,AIT)是否有助于改善原发性肝细胞癌的临床疗效。方法:选取2016年8月至2018年12月在中国人民解放军总医院第五医学中心确诊的64例原发性肝细胞癌患者,通过分层随机法分为免疫治疗组(n=29)和对照组(n=35)。免疫治疗组患者取60 ml外周血分离制备单个核细胞并在含OKT-3和IL-2的培养基中活化培养,回输前进行质控检测。免疫治疗组中的Ⅰ-Ⅲ期患者(n=14)于一线治疗后接受自体淋巴细胞输注(3个月内输注6次),Ⅳ期患者(n=15)仅接受自体淋巴细胞输注;对照组患者接受肝细胞癌相关的其他治疗。疗效评估的主要终点是2年无复发生存(relapse-free survival,RFS)率,次要终点为无进展生存期(progression-free survival,PFS)和总生存期(overall survival,OS)。结果:入组患者中位随访时间为2.8年(0.2-4.2年)。免疫治疗组29名患者共接受了167次(计划174次,完成率96%)预定淋巴细胞输注(平均每人次回输9.30×10^(9)个细胞,其中CD3^(+)HLA-DR细胞约占63%),治疗期间未观察到3级或4级不良反应发生。与对照组相比,免疫治疗组患者2年RFS率显著升高(62.1%vs 22.9%,OR=0.181,95%CI:0.06-0.54,P=0.002),中位PFS(28 vs 8个月,P=0.004)和中位OS(38 vs 34个月,P=0.915)均显著延长。在Ⅰ-Ⅲ期患者中,免疫治疗组(n=14)2年RFS率较对照组(n=18)显著升高(92.9%vs 33.3%,OR=0.38,95%CI:0.004-0.368,P=0.005),中位PFS明显延长(38 vs 14.5个月,P=0.005),而两组OS间无显著差异;Ⅳ期患者两组间PFS(P=0.077)及OS(P=0.994)均未见显著差异。结论:活化自体淋巴细胞AIT为安全可行的肝细胞癌辅助性治疗方法,可提高Ⅰ-Ⅲ期肝细胞癌一线治疗后RFS率、延长患者RFS时间,而对进展期肝细胞癌患者的PFS和OS无明显影响。展开更多
Breast Conserving Surgery (BCS) is a rapidly emerging field increasingly adopted to facilitate breast conservation and preserve breast aesthetics. Since the publicatio</span><span style="font-family:Verd...Breast Conserving Surgery (BCS) is a rapidly emerging field increasingly adopted to facilitate breast conservation and preserve breast aesthetics. Since the publicatio</span><span style="font-family:Verdana;">n of the Randomized Controlled Trials (RCTs) of Breast Conserving Surgery versus mastectomy in early breast cancer, the adoption of BCS for breast cancer patients’ surgical management has been comprehensive. A computerized bibliographic search was performed on PubMed/MEDLINE,</span><span style="font-family:Verdana;"> Embase, Google Scholar and Cochrane library databases. This article aims to perform a thorough review of new data regarding invasive cancer and margins while evaluating patient outcomes related to BCS after neoadjuvant chemotherapy focusing on margins, imaging evaluation, the extent of resection, and local regional recurrence outcomes. The growth pattern and biopsy of Ductal Carcinoma </span><i><span style="font-family:Verdana;">In Situ</span></i><span style="font-family:Verdana;"> (DCIS) differ from invasive cancer, impacting margins. It is essential to understand how the Society of Surgical Oncology (SSO) DCIS margin guideline has influenced practice. Early breast cancer surgical management should be unique to each patient, driven by evidence-based medicine, and focused on specific clinical, histological, and molecular characteristics of the tumor. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">The current management for early breast cancer should be tailored and evidence-based to each patient based on the clinical, histological and molecular characteristics of the tumor. Presumably, the standard of care in BCS has enhanced the outcomes for this patient population. This review made by peers will help surgeons to stay up to date with the current literature and help them manage breast cancer while improving multiple clinical parameters such as Disease-Free Survival (DFS), Recurrence-Free Survival (RFS) and most importantly Overall Survival (OS)</span></span></span><span style="font-family:Verdana;">.展开更多
Objective: Colon cancer is one of the most common human malignancies. Cancer stem cells(CSCs), despite being only a small subset of cancer cells, have the capability to self-renew and sustain the tumor. They also have...Objective: Colon cancer is one of the most common human malignancies. Cancer stem cells(CSCs), despite being only a small subset of cancer cells, have the capability to self-renew and sustain the tumor. They also have the ability to proliferate. Multiple CSCs-associated markers have been identified in colon cancer including CD133, ALDH1 and β-catenin. The aim of the work was to study the prognostic value of CSCs markers(CD133, ALDH1 and β-catenin), as well as their relationship to clinicopathological features of colon cancer. Methods: CD133, ALDH1 and β-catenin proteins expression was assessed immunohistochemically in a series of colon cancers and their prognostic significance was evaluated. Results: CD133 expression showed significant relationship to tumor stage and lymph node metastasis(P-value 0.004 & < 0.001 respectively), and near significant relationship to liver metastasis(P-value 0.092). ALDH1 was significantly associated with tumor grade, stage and nodal metastasis(P-value 0.021, 0.001 and 0.026 respectively), but its relationship to liver metastasis was near significant(P-value 0.068). Nuclear β-catenin was significantly related to tumor grade, stage, nodal and liver metastasis(P-value 0.001, < 0.001, < 0.001 and 0.008 respectively). Overall survival(OS) was associated inversely with CD133, ALDH1 positivity, and directly with nuclear β-catenin positivity(P-value < 0.001, 0.0001 and < 0.001 respectively). Also recurrence free survival(RFS) was associated inversely with CD133, ALDH1 and directly with nuclear β-catenin positivity(P-value 0.0001, 0.001 and < 0.001 respectively). Conclusion: CD133, ALDH1 and β-catenin expressions of tumor cells have significant impact upon malignant progression of colon cancer and thus patient survival and tumor recurrence. Hence they can be used to predict outcome of colon cancer patients.展开更多
Background:Liver resection and local ablation are the only curative treatment for non-cirrhotic hepatocellular carcinoma(HCC).Few data exist concerning the prognosis of patients resected for non-cirrhotic HCC.The obje...Background:Liver resection and local ablation are the only curative treatment for non-cirrhotic hepatocellular carcinoma(HCC).Few data exist concerning the prognosis of patients resected for non-cirrhotic HCC.The objectives of this study were to determine the prognostic factors of recurrence-free survival(RFS)and overall survival(OS)and to develop a prognostication algorithm for non-cirrhotic HCC.Methods:French multicenter retrospective study including HCC patients with non-cirrhotic liver without underlying viral hepatitis:F0,F1 or F2 fibrosis.Results:A total of 467 patients were included in 11 centers from 2010 to 2018.Non-cirrhotic liver had a fibrosis score of F0(n=237,50.7%),F1(n=127,27.2%)or F2(n=103,22.1%).OS and RFS at 5 years were 59.2%and 34.5%,respectively.In multivariate analysis,microvascular invasion and HCC differentiation were prognostic factors of OS and RFS and the number and size were prognostic factors of RFS(P<0.005).Stratification based on RFS provided an algorithm based on size(P=0.013)and number(P<0.001):2 HCC with the largest nodule≤10 cm(n=271,Group 1);2 HCC with a nodule>10 cm(n=176,Group 2);>2 HCC regardless of size Conclusions:We developed a prognostication algorithm based on the number(≤or>2)and size(≤or>10 cm),which could be used as a treatment decision support concerning the need for perioperative therapy.In case of bifocal HCC,surgery should not be a contraindication.展开更多
文摘目的:评价活化自体淋巴细胞过继性免疫治疗(adoptive immunotherapy,AIT)是否有助于改善原发性肝细胞癌的临床疗效。方法:选取2016年8月至2018年12月在中国人民解放军总医院第五医学中心确诊的64例原发性肝细胞癌患者,通过分层随机法分为免疫治疗组(n=29)和对照组(n=35)。免疫治疗组患者取60 ml外周血分离制备单个核细胞并在含OKT-3和IL-2的培养基中活化培养,回输前进行质控检测。免疫治疗组中的Ⅰ-Ⅲ期患者(n=14)于一线治疗后接受自体淋巴细胞输注(3个月内输注6次),Ⅳ期患者(n=15)仅接受自体淋巴细胞输注;对照组患者接受肝细胞癌相关的其他治疗。疗效评估的主要终点是2年无复发生存(relapse-free survival,RFS)率,次要终点为无进展生存期(progression-free survival,PFS)和总生存期(overall survival,OS)。结果:入组患者中位随访时间为2.8年(0.2-4.2年)。免疫治疗组29名患者共接受了167次(计划174次,完成率96%)预定淋巴细胞输注(平均每人次回输9.30×10^(9)个细胞,其中CD3^(+)HLA-DR细胞约占63%),治疗期间未观察到3级或4级不良反应发生。与对照组相比,免疫治疗组患者2年RFS率显著升高(62.1%vs 22.9%,OR=0.181,95%CI:0.06-0.54,P=0.002),中位PFS(28 vs 8个月,P=0.004)和中位OS(38 vs 34个月,P=0.915)均显著延长。在Ⅰ-Ⅲ期患者中,免疫治疗组(n=14)2年RFS率较对照组(n=18)显著升高(92.9%vs 33.3%,OR=0.38,95%CI:0.004-0.368,P=0.005),中位PFS明显延长(38 vs 14.5个月,P=0.005),而两组OS间无显著差异;Ⅳ期患者两组间PFS(P=0.077)及OS(P=0.994)均未见显著差异。结论:活化自体淋巴细胞AIT为安全可行的肝细胞癌辅助性治疗方法,可提高Ⅰ-Ⅲ期肝细胞癌一线治疗后RFS率、延长患者RFS时间,而对进展期肝细胞癌患者的PFS和OS无明显影响。
文摘Breast Conserving Surgery (BCS) is a rapidly emerging field increasingly adopted to facilitate breast conservation and preserve breast aesthetics. Since the publicatio</span><span style="font-family:Verdana;">n of the Randomized Controlled Trials (RCTs) of Breast Conserving Surgery versus mastectomy in early breast cancer, the adoption of BCS for breast cancer patients’ surgical management has been comprehensive. A computerized bibliographic search was performed on PubMed/MEDLINE,</span><span style="font-family:Verdana;"> Embase, Google Scholar and Cochrane library databases. This article aims to perform a thorough review of new data regarding invasive cancer and margins while evaluating patient outcomes related to BCS after neoadjuvant chemotherapy focusing on margins, imaging evaluation, the extent of resection, and local regional recurrence outcomes. The growth pattern and biopsy of Ductal Carcinoma </span><i><span style="font-family:Verdana;">In Situ</span></i><span style="font-family:Verdana;"> (DCIS) differ from invasive cancer, impacting margins. It is essential to understand how the Society of Surgical Oncology (SSO) DCIS margin guideline has influenced practice. Early breast cancer surgical management should be unique to each patient, driven by evidence-based medicine, and focused on specific clinical, histological, and molecular characteristics of the tumor. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">The current management for early breast cancer should be tailored and evidence-based to each patient based on the clinical, histological and molecular characteristics of the tumor. Presumably, the standard of care in BCS has enhanced the outcomes for this patient population. This review made by peers will help surgeons to stay up to date with the current literature and help them manage breast cancer while improving multiple clinical parameters such as Disease-Free Survival (DFS), Recurrence-Free Survival (RFS) and most importantly Overall Survival (OS)</span></span></span><span style="font-family:Verdana;">.
文摘Objective: Colon cancer is one of the most common human malignancies. Cancer stem cells(CSCs), despite being only a small subset of cancer cells, have the capability to self-renew and sustain the tumor. They also have the ability to proliferate. Multiple CSCs-associated markers have been identified in colon cancer including CD133, ALDH1 and β-catenin. The aim of the work was to study the prognostic value of CSCs markers(CD133, ALDH1 and β-catenin), as well as their relationship to clinicopathological features of colon cancer. Methods: CD133, ALDH1 and β-catenin proteins expression was assessed immunohistochemically in a series of colon cancers and their prognostic significance was evaluated. Results: CD133 expression showed significant relationship to tumor stage and lymph node metastasis(P-value 0.004 & < 0.001 respectively), and near significant relationship to liver metastasis(P-value 0.092). ALDH1 was significantly associated with tumor grade, stage and nodal metastasis(P-value 0.021, 0.001 and 0.026 respectively), but its relationship to liver metastasis was near significant(P-value 0.068). Nuclear β-catenin was significantly related to tumor grade, stage, nodal and liver metastasis(P-value 0.001, < 0.001, < 0.001 and 0.008 respectively). Overall survival(OS) was associated inversely with CD133, ALDH1 positivity, and directly with nuclear β-catenin positivity(P-value < 0.001, 0.0001 and < 0.001 respectively). Also recurrence free survival(RFS) was associated inversely with CD133, ALDH1 and directly with nuclear β-catenin positivity(P-value 0.0001, 0.001 and < 0.001 respectively). Conclusion: CD133, ALDH1 and β-catenin expressions of tumor cells have significant impact upon malignant progression of colon cancer and thus patient survival and tumor recurrence. Hence they can be used to predict outcome of colon cancer patients.
文摘Background:Liver resection and local ablation are the only curative treatment for non-cirrhotic hepatocellular carcinoma(HCC).Few data exist concerning the prognosis of patients resected for non-cirrhotic HCC.The objectives of this study were to determine the prognostic factors of recurrence-free survival(RFS)and overall survival(OS)and to develop a prognostication algorithm for non-cirrhotic HCC.Methods:French multicenter retrospective study including HCC patients with non-cirrhotic liver without underlying viral hepatitis:F0,F1 or F2 fibrosis.Results:A total of 467 patients were included in 11 centers from 2010 to 2018.Non-cirrhotic liver had a fibrosis score of F0(n=237,50.7%),F1(n=127,27.2%)or F2(n=103,22.1%).OS and RFS at 5 years were 59.2%and 34.5%,respectively.In multivariate analysis,microvascular invasion and HCC differentiation were prognostic factors of OS and RFS and the number and size were prognostic factors of RFS(P<0.005).Stratification based on RFS provided an algorithm based on size(P=0.013)and number(P<0.001):2 HCC with the largest nodule≤10 cm(n=271,Group 1);2 HCC with a nodule>10 cm(n=176,Group 2);>2 HCC regardless of size Conclusions:We developed a prognostication algorithm based on the number(≤or>2)and size(≤or>10 cm),which could be used as a treatment decision support concerning the need for perioperative therapy.In case of bifocal HCC,surgery should not be a contraindication.